We’re proud of our collaborative culture and the ways our people come together with the goal of helping patients. The teams that are part of our REGENXBIO Manufacturing Innovation Center (RMIC) are a prime example of collaboration in action. Hear from Katie Masterson, Senior Director of Manufacturing Operations about how our manufacturing capabilities set us apart.
REGENXBIO Inc.
Biotechnology Research
Rockville, Maryland 32,723 followers
Seeking to improve lives through the curative potential of gene therapy.
Über uns
REGENXBIO is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno‐associated virus (AAV) gene therapy. REGENXBIO's NAV® Technology Platform, a proprietary AAV gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO's mission is to transform the lives of patients suffering from severe diseases with significant unmet medical need by developing and commercializing in vivo gene therapy products based on REGENXBIO's NAV Technology Platform. REGENXBIO seeks to accomplish this mission through a combination of internal development efforts and third‐party NAV Technology Platform licensees.
- Website
-
https://www.regenxbio.com
External link for REGENXBIO Inc.
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 201-500 Mitarbeiter
- Hauptsitz
- Rockville, Maryland
- Typ
- Öffentliches Unternehmen
- Gegründet
- 2008
- Spezialitäten
- Biotechnology, Biopharmaceuticals, and Gene Therapy
Standorte
-
Primäre
9804 Medical Center Dr
Rockville, Maryland 20850, US
Employees at REGENXBIO Inc.
Aktualisierungen
-
Yesterday, we were honored to welcome Katie Morgan and her son Andy, who lives with Duchenne, to REGENXBIO. Andy’s energy and enthusiasm, especially when sharing his hobbies and exploring our labs and manufacturing facilities, brought smiles to everyone’s faces. It was a privilege to learn about their journey with Duchenne. We ended the day with a walk to support Parent Project Muscular Dystrophy. Thank you, Katie and Andy, for spending the day with us!
-
Today on World Duchenne Awareness Day, REGENXBIO joins the Duchenne community to spread awareness of this rare degenerative muscle disease. This year’s theme, Raise Your Voice for Duchenne, highlights the importance of amplifying the voices of those living with Duchenne. To honor this day, the World Duchenne Organization premiered a special documentary showcasing the incredible resilience, determination, and journeys of people living with Duchenne across the globe. Their stories of challenges and triumphs remind us of the importance of community and advocacy. https://lnkd.in/etwKajNr
-
As we approach World Duchenne Awareness Day, meet Dr. Jahannaz Dastgir, a neuromuscular neurologist and the clinical development lead for our RGX-202 program for Duchenne.
-
September is Newborn Screening Awareness month, which raises public awareness of the importance of newborn screenings in supporting early detection of genetic diseases and enabling potentially life-changing early interventions. Hand in hand with the rare disease community, we advocate for the widespread implementation of newborn screening. Learn more from our partner, EveryLife Foundation for Rare Diseases: https://lnkd.in/ez4CduDj
-
Today, we announced positive results from our pivotal CAMPSIITE® trial of RGX-121 for the treatment of MPS II, also known as Hunter syndrome, presented at the SSIEM 2024 Annual Symposium. With our upcoming BLA submission using the accelerated approval pathway, RGX-121 is on track to be the first potential first gene therapy and one-time treatment for MPS II, and the first treatment in the U.S. that addresses the neurocognitive decline associated with this disease. Learn more: https://lnkd.in/gZgtGsyB #SSIEM #SSIEM24
-
REGENXBIO will participate in upcoming investor conferences. Learn more: https://lnkd.in/eVY8GS-N
-
At REGENXBIO, innovation isn’t just a buzzword; it’s one of our core values and is woven into the fabric of our culture and work. Hear from Ye Liu, VP of Gene Therapy Research on why he thinks REGENXBIO is transforming gene therapy research.
-
Our Batten disease programs are now in great hands with Tern Therapeutics. We look forward to following their advancement and impact on the CLN2 community.
Tern Therapeutics is excited to announce its launch and financing: https://lnkd.in/e5WvwDn4
Ähnliche Seiten
Jobs durchsuchen
Aktie
RGNX
NASDAQ
20 Minuten Verzögerung
$12.84
0.66 (5.419%)
- Öffnen Sie
- 12.28
- Niedrig
- 12.19
- Hoch
- 12.97
Daten von Refinitiv
Siehe mehr Informationen aufFinanzierung
Letzte Runde
Eigenkapital nach dem IPOUS$ 140.0M